What Every Pharmaceutical CFO Needs To Know About Government Pricing Programs

Since 2002, more than $5 billion in fines have been levied against pharmaceutical and biotech companies by the government for Medicare and Medicaid price violations. The Office of CFO, with critical support from the audit committee and legal counsel, has become the primary gatekeeper against potential damage to revenue confidence, shareholder value and brand image resulting from prosecution.

Join government programs experts Joel Winterton of S•E•T Enterprises and Joseph Metro, partner at Reed Smith, for insights on how your organization can reduce financial and regulatory risk in today's complex business environment.

Click here to request your free White Paper!

Publisher: